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Summary 
Experimental autoimmune myasthenia gravis (EAMG) is an animal model of human myasthe- 
nia gravis (MG).  In mice, EAMG is induced by immunization with  Torpedo  californica acetyl- 
choline receptor (AChK)  in complete Freund's adjuvant (CFA).  However, the role of cyto- 
kines  in  the  pathogenesis  of EAMG  is  not  clear.  Because  EAMG  is  an  antibody-mediated 
disease,  it is of the prevailing notion that Th2 but not Thl  cytokines play a role in the patho- 
genesis of this disease.  To test the hypothesis that the Thl cytokine, interferon (IFN)I'y, plays a 
role in the development of EAMG, we immunized IFN-~ knockout (IFN-gko) (-/-)  mice 
and wild-type (WT)  (+/+)  mice of H-2  b haplotype with AChlL in CFA. We observed that 
AChtL-primed lymph node cells from IFN-gko mice proliferated normally to AChlL and to its 
dominant pathogenic 0d46-162 sequence when compared with these cells from the WT mice. 
However, the IFN-gko mice had no signs of muscle weakness and remained resistant to clinical 
EAMG at a time when the WT mice exhibited severe muscle weakness and some died.  The 
resistance  of IFN-gko  mice  was  associated  with  greatly  reduced  levels  of circulating  anti- 
AChlL antibody levels compared with those in the WT mice.  Comparatively, immune sera 
from IFN-gko mice showed a dramatic reduction in mouse AChR-specific IgG1 and IgG2a 
antibodies.  However, keyhole limpet hemocyanin  (KLH)-priming of IFN-gko mice readily 
elicited both T  cell and antibody responses, suggesting that IFN-~/regulates the humoral im- 
mune  response distinctly  to  self (AChR)  versus foreign  (KLH)  antigens.  We  conclude  that 
IFN-~/is required for the generation of a pathogenic anti-AChR humoral immune response 
and for conferring susceptibility of mice to clinical EAMG. 
M  yasthenia gravis (MG) 1 is a T  cell-dependent antibody- 
.mediated disease whose hallmark is an autoimmune 
neuromuscular disorder (1). The cause is a loss of functional 
acetylcholine receptors (AChtL) at the postsynaptic membrane, 
mediated by autoantibodies (AAbs) and complement (2). Ex- 
perimental autoimmune MG (EAMG) is a well-established an- 
imal model for exploring the pathogenesis of this disease in 
humans. In EAMG, the autoimmune destruction of AChR 
produces a defect in neuromuscular transmission  causing the 
characteristic  muscle  weakness  and  fatigue  of the  disease. 
EAMG can be induced in mice of the H-26 haplotype by 
repeated immunizations with AChR emulsified in CFA (3). 
1Abbreviations used in this paper: AAbs, autoantibodies; AChlL, acetylcholine 
receptor; EAMG, experimental  autoinmaune myasthenia gravis; HILPO, 
horseradish peroxidase; IFN-gko,  IFN-"/knockout;  LNC, lymph  node cells; 
M-AChtL, mouse  AChR_; MG, myasthenia  D-avis;  NMS, normal  mouse  serum. 
The  role  of cytokines  in  the  immunopathogenesis  of 
AChlL-induced EAMG is not clear. Because EAMG is an 
antibody-mediated disease, it has been thought Th2 cyto- 
kines play a major role in the pathogenesis of this disease. 
The prevailing notion in autoimmunity is that Thl  cyto- 
kines (IFN-~/) are associated with cell-mediated rather than 
antibody-mediated diseases.  However, in previous studies 
from our laboratory, the  ectopic  expression of proinflam- 
matory Thl  cytokine  IFN-~/ in  the  neuromuscular junc- 
tion ehcited a humoral IgG response to an unidentified an- 
tigen  within  the  motor  end  plate,  yielding  a  MG-like 
syndrome in  mice  (4).  Therefore,  we  tested  here  the  re- 
quirement of IFN-~ in the development of AChR-induced 
EAMG in mice. For this purpose, we used IFN-~ knock- 
out (IFN-gko) mice in which IFN-~/gene activity was dis- 
rupted and wild-type  (WT)  mice whose IFN-~/ gene was 
intact. 
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Mice.  IFN-gko  mice  of the  H-2  b haplotype  (5)  were  pro- 
vided by Dr. D. Dalton (Trudeau Institute, NY).  Heterozygous 
IFN-gko  (+/-)  (129/SvEv  X  C57BL/6)F1  mice  were  inter- 
crossed in our animal facility to generate homozygous (-/-)  gko 
(129/SvEv ×  C57BL/6) F2 mice. WT (129/SVJ  X  C57BL/6)F2 
mice  (+/+)  were  used as positive control mice and were pur- 
chased from The Jackson Laboratory (Bar Harbor, ME). In addi- 
tion, C57BL/6 mice were used as additional controls (The Jack- 
son Laboratory). Both  129/SVJ  and 129/SvEV are derived from 
the  same parental strain.  The  difference between the  two  sub- 
strains is that the SvEv was crossed once with C3H, then the F1 
were  backcrossed again 14  times back to  Sv parental strain but 
SvEv substrain is  very much  (99.99%)  similar to  Svj  (6).  Mice 
were 8- to  10-wk-old when used in the experiments in compli- 
ance with institutional guidelines. 
Isolation of Genomic DNA and PCR.  IFN-gko (-/-)  mice were 
screened by PCK of tail DNA. An aliquot of the genomic DNA 
was amplified in a  PCR  using primers binding to the neo gene 
(Neo490V, 5'-CGGTTCTTTTTGTCAAGAC-3';  NB3, 5'-ATC- 
CTCGCCGTCGGGC ATGC-3') (391-bp product) and exon 2 
and  3  of  the  IFN  gene  (A1,  5'-AAGTGGCATAGATGT- 
GGAAG-3'; B1, 5'-GAATGCATCCTTTTTCGCCT-3') (223- 
bp product). PC1K conditions were as follows: one step at 94°C for 
1 rain, 30 s; then 33 cycles of 94°C for 1 rain, 55°C for 1 rain, 
and 72°C for 1 nfin. The final step was at 72°C for 5 rain. 
Antigens.  AChR. was purified from Triton X-100 extracts of 
electric organ membranes from Torpedo californica by affinity chro- 
matography on a conjugate ofet-bungarotoxin coupled to agarose (7). 
AChR-ed46-162 peptide LGIWTYDGTKVS1SPES (8) was syn- 
thesized at >70% purity. KLH (Cal Biochem, San Diego, CA), OVA 
(Sigma Chemical Co., St. Louis, MO), purified protein derivative 
(PPD; Statens Seruminstitute, Copenhagen, Denmark), and Con A 
(Pharmacia Biotech, Piscataway,  NJ) were purchased as designated. 
Lymphocyte Proliferation Assay.  Mice  were  immunized at  the 
base of the tail with 20 p~g of AChR or 100 p,g of KLH in 100 ILl 
of CFA  emulsion. After 5  d  of immunization, the  mice  were 
killed,  and their draining para  aortic  and inguinal lymph node 
cells (LNC) were cultured in 0.2 ml oflKPMI-10 at 4  ×  10S/well 
in 96-well,  flat-bottomed microtiter plates  (Becton  Dickinson, 
Franklin Lakes,  NJ)  with  and  without  AChlK  (10  p~g/ml)  or 
c¢146-162 peptide  (20  vg/ml). KLH and OVA were used at 50 
p~g/ml and 20 p~g/ml, respectively. IKPMI-  10 consisted of 1KPMI- 
1640 supplemented with 10% heat-inactivated fetal bovine serum, 
20 mM Hepes, 3 X  10 -5 M  2-ME, 2 X  10 -3 M  t-glutamine, 100 
U/ml penicillin, and 100 p,g/ml streptomycin. Cultures were in- 
cubated for 4 d at 37°C in humidified 5% CO2-enriched air and 
were pulsed with 1 vCi [3H]TdR/well during the last 18 h of in- 
cubation. [3H]TdR uptake was measured in a Beckman [3 scintil- 
lation counter. The results were expressed as a stimulation index, 
i.e., (mean cpm with antigen) /  (mean cpm without antigen). 
Cytokine ELISA.  Single cell suspensions of draining LNC of 
AChR-primed mice were  cultured at  106/ml in 1KPMI-10 and 
2.5 p,g/ml AChR in 24-well, flat-bottomed plates (Coming Glass 
Works,  Coming, NY)  at 37°C in 5%  CO2 and 95% humidity. 
The supematants were collected after 48 h  of in vitro boosting. 
An ELISA kit was used for detection of IFN-"/(PharMingen, San 
Diego,  CA).  Concentrations of IFN-',/were determined using a 
standard curve based on known quantities of mouse recombinant 
IFN-~/(Genzyme, Cambridge, MA). 
Induction and Assessment of EAMG.  Groups of mice  (n  =  13 
to 15) were immunized subcutaneously in both hind footpads and 
at two shoulder regions with 20 p,g of Torpedo californica AChR in 
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CFA (Mycobacterium tuberculosis, H371Ka) (Difco Laboratories, De- 
troit, MI). Each site received "-'5 p~g of AChR in 50 p,1 of emul- 
sion. Mice were boosted on days 30 and 75 with 20 p,g of AChIk 
in CFA at selected sites in the shoulders and also in thigh regions 
(four sites). In a blind study, these mice were assessed daffy for the 
characteristic symptom of EAMG: muscle weakness graded from 
0 to 3 as described earlier (3). Muscle weakness attributable to MG 
was further confirmed by administering intraperitoneally the anti- 
cholinesterase, neostigmine bromide, combined with atrophine sul- 
fate, and assessing for temporary improvement in muscle strength (4). 
Radioimmunoassay for Anti-mouse-A ChR (M-A ChR) Abs.  Se- 
rum anti-M-AChR Ab levels were determined by using an es- 
tablished protocol  (7).  M-AChlK (1  ×  10 -9)  was  incubated at 
4°C in Triton buffer with [12sI]cx-bungarotoxin (2 ×  10 -9 M) for 
4 h.  To 1 ml of labeled M-AChlK,  1 p,1 sera from experimental 
mice was added. Normal mouse serum (NMS) was used as a con- 
trol. After overnight reaction at 4°C, rabbit anti-mouse Ig (100 p,1) 
was added. After 4-h incubation at room temperature, the tubes 
were  centrifuged, and the pellet was  washed with  1 ml Triton 
buffer, centrifuged again, and counted in a ~/counter. The differ- 
ence in AChlK counts precipitated in the experimental versus the 
control samples was used to calculate the Ab response in nano- 
moles of toxin binding sites per liter of serum. 
ELISA for IgG Isotype Determination.  Anti-M-AChR responses 
were measured as described earlier (9). The 96-well flat-bottomed 
polysterene plates  (Coming Glass  Works,  Coming,  NY)  coated 
with  M-AChlK  (0.5  Ixg/ml)  in  0.1  M  carbonate-bicarbonate 
buffer (pH 9.6) were incubated overnight at 4°C. The wells were 
blocked with 2% BSA in PBS at room temperature for 30 rain. 
Serum samples  (diluted 1:4,000 for IgG1, and IgG2b;  1:200 for 
IgG2a) were added and incubated at 37°C for 90 rain. After four 
washes,  horseradish  peroxidase  (HRPO)-conjugated  goat  anti- 
mouse  IgG  isotypes  (1:2,000)  (CALTAG Labs.,  San  Francisco, 
CA) were added and incubated at 37°C for 90 rain. After washing 
the plates, 0.3 mg/ml 2.2'-Azino-di 3-athyl benzthiazolinsulfonat 
(Boehringer Mannheim GmbH, Mannheim, Germany) substrate 
solution was added and allowed to develop color at room tem- 
perature in the dark. Serially diluted anti-AChR and NMS were 
used as positive and negative controls, respectively. Plates were 
read at 0D410 nm and results were expressed as OD values. 
Measurement of the Ab Response to KLH.  Mice  (n  =  6)  were 
primed with 100 p~g KLH in CFA on day 0 and boosted on days 
30 and 75 as in the AChlK immunization protocol.  In brief, we 
coated the  96-well flat-bottomed plates  (Coming Glass  Works, 
Coming,  NY)  with  5  p,g/ml  KLH  in PBS  overnight at  4°C. 
Later, the wells were blocked for 2 h at 37°C with PBS contain- 
ing 1% BSA, 10% heat-inactivated fetal bovine serum, and 0.05% 
Tween-20. Immune sera (diluted 1:800,000 for IgG1; 1:6,400 for 
IgG2a) were added and incubated for 2  h  at room temperature. 
For IgG isotype measurement, HRPO-labeled Ab to murine IgG 
isotypes was used at 1:2,000 dilution in plates incubated for 2 h at 
room temperature. After three washes, color was developed with 
the substrate, 0-phenylene-diamine  dihydrochloride (Sigma Chem- 
ical Co.), and OD read at 492 nm. Serially diluted anti-KLH sera 
and NMS  were  used as positive and negative controls,  respec- 
tively. The results were expressed as OD values. 
Results 
The  IFN- T  Gene  Disruption  Prevents  the  AChR-induced 
Clinical EAMG.  To test the hypothesis that IFN-',/plays a 
Experimental Autoimmune Myasthenia gravis in IFN-'y--deficient  Mice Table 1.  Ablation of Endogenous IFN-y Prevents the Development of AChR-induced EAMG in Mice 
Muscle weakness (grade)  No. of mice 
No. of mice  died due to 
In vivo  per group  0  1  2  3  severe disease  Disease incidence 
IFN-gko (-/-)  14  14  ....  0/15  (0%) 
Wild type (+/+)  13  1  7  3  2  2  12/13 (92.3%) 
C57BL/6 (+/+)  15  2  6  4  1  2  13/15 (86.7%) 
Clinical manisfestation  of EAMG was graded as follows: grade 0 indicated no muscle weakness even a~er exercise consisting  of 20--30 consecutive 
paw grips on cage top steel grids. Grade 1 was defined as normal at rest, but weak with chin on the floor and inability to raise head after exercise. 
Grade 2 was defined as grade 1 weakness at rest. Grade 3 was moribund, dehydrated, or paralyzed. Clinical EAMG was further confirmed by assess- 
ing for temporary improvement after administering  a combination neostigmine bromide and atrophine sulfate (4). 
role in the development ofAChR-induced EAMG of sus- 
ceptible H-2  b mice, we immunized C57BL/6 (+/+)  (n = 
15), WT  (+/+)  (n =  13), and IFN-gko (-/-)  (n =  14) 
mice with 20 I~g of AChR in CFA on day 0 and again on 
days 30  (first  boost)  and 75  (second boost). After the first 
boost, the mice were monitored daily for clinical symptoms 
(muscle weakness)  of EAMG.  The  final results appear in 
Table  1.  At  39  d  after  the  first  immunization, 7  of  15 
C57BL/6  (+/+)  mice and 8  of 13 WT  (+/+)  mice de- 
veloped  muscle weakness,  but  none of the  14  IFN-gko 
(-/-)  mice  exhibited such weakness.  At  42  d  after first 
immunization, one C57BL/6 (+/+)  mouse died from se- 
vere  clinical EAMG;  then  11  and  14  d  later,  two  more 
died. Although none of the WT  (+/+)  mice died as a re- 
sult of severe disease, two were killed for humanitarian rea- 
sons because of their severe muscle weakness 11  d after the 
second  boost.  However,  the  IFN-gko  (-/-)  mice  re- 
mained resistant to clinical EAMG (P values: IFN-gko ver- 
sus WT  --  <0.001; P value: IFN-gko versus C57BL/6  = 
<0.001).  These results indicate that IFN-',/ influences the 
genesis of EAMG. 
The IFN- T Gene Disruption Does Not Impair the Prolifera- 
tion of Lymphocytes in  Response to ¢IChR and Its Dominant 
Epitope ee146-162.  CD4 + T  cells reactive to AChR and 
its dominant oe146-162 peptide are pivotal in the ability of 
B  cells to generate pathogenic anti-AChR Abs (3,  10-12). 
To address whether the resistance of IFN-gko (-/-)  mice 
results  from  their  inability to  evoke  T  cell  responses  to 
AChR and its oe146-162 peptide, we immunized  WT (+/+) 
and IFN-gko (-/-)  mice with 20 I~g of AChR in CFA. 5 d 
later,  proliferation of their draining LNC was  assayed.  As 
illustrated  in  Fig.  1  A,  the  AChR-primed  LNC  from 
C57BL/6  and  WT  (+/+)  mice  proliferated  strongly in 
response  to  AChR,  as  expected.  LNC  from  IFN-gko 
(-/-)  mice also proliferated significantly  against the AChR. 
Significant proliferative  responses  (SI  =  25.5  _+  1.8)  to 
od46-162  peptide  of  AChR  were  also  observed  with 
AChR-primed LNC from IFN-gko mice (data not shown). 
A similar magnitude of proliferative responses were observed 
with LNC from IFN-gko and control group mice after 14 d 
of AChR  priming (data  not shown).  Interestingly, when 
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Figure 1.  (A) Effect oflFN-~¢ gene disruption on in vitro lymphocyte 
proliferation in response to  AChR  (10  ~g/ml)  and  control antigen 
(OVA; 20 I.tg/ml) on day 5 after immunization with 20 ~g AChP~ in 
CFA. Results were expressed as a stimulation  index. Background  cpm in 
the absence of antigen for C57BL/6, WT, and IFN-gko mice are as fol- 
lows: 1,019, 1,039, 3,443. (B). Effect of IFN-'y gene disruption on in 
vitro lymphocyte  proliferation  m response to KLH (50 ~g/ml) and con- 
trol antigen (OVA; 20 Ftg/ml) on day 5 after immunization  with 100 p.g 
KLH in CFA. Background cpm in the absence of antigen for C57BL/6, 
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R.IA of serum anti-AChR Ab to mouse muscle AChR. Se- 
rum samples were collected on day 89 after immunization. The difference 
in anti-AChR  antibody levels between WT and IFN-gko mice (P = 
0.002) and between C57BL/6 and IFN-gko mice (P = 0.003) was statis- 
tically significant. The difference in anti-ACht(  antibody levels between 
WT and C57BL/6 mice (P =  0.222) is not statistically significant. --*, 
the mean value. 
the mice were immunized with KLH, the intensity of the 
proliferative response of draining LNC from IFN-gko (-/-) 
and WT (+/+)  mice appear similar (Fig.  1 B). Further ex- 
amination  of IFN-~/levels in the culture supernatants  col- 
lected 48 h after an in vitro boost with AChR revealed the 
presence  of IFN-'y in cultured LNC of the  C57BL/6 and 
WT  (+/+)  mice  but  not  of the  IFN-gko  (-/-)  mice 
(data not shown). 
The  IFN-T  Gene  Disruption Dramatically  Affects  Serum 
Anti--AChR Ab Response.  The primary pathology of  EAMG, 
the end plate AChR loss, stems from the deleterious effect 
of pathogenic AAbs to the AChR  (2).  Therefore,  to learn 
whether a  reduced anti-AChiL Ab response  underlies  the 
resistance  of IFN-gko  (-/-)  mice  to  EAMG,  we  used 
ILIA to compare their levels of serum anti-M-AChR Ab to 
those in C57BL/6 (+/+),  and WT (+/+)  mice on day 89 
after immunization with AChR in CFA. The results appear 
in Fig. 2. The results indicate th~/t the resistance of the mu- 
tants  (-/-)  to EAMG  correlated  with  their dramatic  de- 
crease in the level of AAbs to ACbR compared with signifi- 
candy higher levels in the C57BL/6 (+/+)  and WT (+/+) 
mice.  The individual AChR-immunized C57BL/6  (+/+) 
and WT  (+/+)  mice responded heterogeneously. A  wide 
heterogeneity in anti-AChIL response has earlier been doc- 
umented in inbred C57BL/6 mice (13). However, we did 
not find a correlation between the anti-AChtk antibody re- 
sponse magnitude of individual mice (C57BL/6 and WT) 
and  severity  of EAMG.  Our findings  further  support  the 
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Figure 3.  The effect oflFN-~/gene disruption on anti-AChR Ab iso- 
types (A)  IgG1, (B) IgG2a and anti-KLH Ab isotypes, (C-) IgG1, (D) 
IgG2a. Serum samples were collected on day 89 after the first immuniza- 
tion with AChR or KLH. The differences in IgG1 and IgG2a  responses 
between ACbR-immunized WT and IFN-gko mice were statistically sig- 
nificant; for IgGl response, P = 0.000; for IgG2a response, P = 0.000. *, 
the mean value. 
earlier findings that no correlation exists between the mag- 
nitude of the anti-AChR antibody response and severity of 
EAMG (8,  13-15). 
The  IFN- T  Gene  Disruption Dramatically  Affects  Serum 
Anti-AChR Isotype Response.  Because IFN-~/has been as- 
sociated  with  the  IgG2a  response  (16),  we  examined 
AChR-immunized mice for levels of IgG2a and IgG1 with 
an  IgG  isotype-specific  ELISA.  Comparison  of immune 
sera from IFN-gko (-/-)  mice and WT  (+/+)  mice re- 
vealed  dramatic  reductions  in  both  IgG1  and  IgG2a Ab 
levels in the IFN-gko (-/-)  mice (Fig. 3, A-B). Similarly, 
the  IgG2b and  IgG3 Ab levels of the  latters  were  signifi- 
cantly reduced (data not shown).  Therefore, AChR prim- 
ing of IFN-gko (-/-)  mice apparently failed to elicit sig- 
nificant amounts of Ab in any IgG subclass. 
Finally, to assess whether the observed IgG subclass dis- 
tribution was unique to AChR stimulation,  we used KLH 
as the immunogen. Sera from mice immunized with KLH 
on the  same schedule  used for AChR  priming were sub- 
sequently analyzed for IgG isotypes. As the results in Fig. 
3,  C-D,  show, immune sera from IFN-y-containing WT 
(+/+)  mice,  when  compared  with  such  sera  from IFN- 
gko  (-/-)  mice,  had  decreased  levels  of IgG2a and  in- 
creased levels of IgG1, confirming the association between 
IFN-~/and the IgG2a response (17). 
388  Experimental  Autoimmune Myasthenia gravis in IFN-~/-deficient  Mice Discussion 
Our report documents that IFN-~/is essential for the de- 
velopment of  EAMG in mice. Herein, we demonstrate that 
the lack of  endogenous tFN-~/dramaticaUy affected the hu- 
moral autoimmune response to AChlL and prevented chn- 
ical  disease  in  H-2  b mice.  However, T  cell responses to 
AChP,  were found relatively normal.  Unexpectedly, our 
findings also  demonstrate a dichotomy of the requirement 
for IFN-~/ in the induction of humoral immune response 
to self (AChP,) and foreign (KLH) antigens. 
The EAMG-resistant IFN-gko mice failed to mount sig- 
nificant M-AChR-specific Ab responses (Fig.  2). The im- 
portance of this lapse may be that their AChR-specific Ab 
levels were too low (a) to provoke antigenic modulation at 
the  motor end plate  (18,  19);  (b)  to  competitively block 
AChR  function  (20);  and/or  (c)  to  destroy postsynaptic 
membranes through complement fixation (21, 22), thereby 
preventing immune destruction. 
The IFN-gko (-/-)  and the control WT (+/+)  mice 
used in our study were derived from intercrossing of (129/ 
SvEv ×  C57BL/6)F1 mice and  (129/SVJ  ×  C57BL/6)F1 
mice,  respectively.  Therefore,  the  genetic  origin  (129/Sv 
substrain)  of the  embryonic  stem  cells  used  provides  a 
source of genetic heterogeneity in mice, although the SvEv 
and SvJ substrains  are very (99.99%) much similar (see Ma- 
terials  and Methods). However, this genetic heterogeneity 
may have little influence, if any,  on the dramatic  effect 
that  we  were  measuring.  This  interpretation stems  from 
three  pieces  of observations:  (a)  the  complete  resistance 
(100%)  of IFN-gko mice to chnical EMAG and a higher 
incidence (92.3%)  of disease  in WT mice (Table 1);  (b)  a 
dramatic reduction in anti-M-AChR response in all of the 
IFN-gko mice (Fig. 2); and (c) a similar heterogeneous hu- 
moral immune response among individual WT (+/+)  and 
C57BL/6 mice (Fig. 2). Thus, the simplest and most direct 
interpretation of our findings is that the phenotype (resis- 
tance to EAMG) reflects an effect of IFN-~/. Therefore, the 
resistance of IFN-gko mice to EAMG is attributed to the 
absence of IFN-',/. 
The  dichotomy observed in  the  humoral  immune  re- 
sponse to AChR versus KLH-immunized IFN-gko (-/-) 
mice is unexpected. Because a significant AChR-specific T 
cell proliferative response is observed in WT  (+/+)  and 
IFN-gko  (-/-)  mice,  the loss  of M-AChP,.-specific Ab 
responses in  IFN-gko  (-/-)  mice probably results from 
defective T  cetl-B cell cognate interactions. What role could 
IFN-~/  play in that  process?  It is  known  that T  cells  re- 
sponding  to  self-antigen(s)  are  generally  of low  affinity 
compared with those responding to foreign antigens  (23, 
24).  Additionally, the expression of AChP, in the thymus 
(25) may enhance negative selection of higher affinity au- 
toreactive T  cells,  resulting  in  a  particularly low  affinity 
AChP, T  cell repertoire. During cognate T  cell-B cell in- 
teractions, these AChR-specific low affinity, T cells may re- 
quire a higher level of costimulation to achieve the thresh- 
old for contact-dependent signals  to cause stimulation and 
differentiation of B  cells  and  subsequent  Ab  production. 
Therefore, we  speculate  that  mounting  an  effective hu- 
moral  immune  response  to  this  (AChP,)  self-antigen  is 
IFN-~/ dependent, because the  cytokine regulates the ex- 
pression of costimulatory molecules (26, 27). On the other 
hand, the KLH-specific high affinity T  cells do not require 
IFN-3~-dependent costimulation by B cells to effectively  par- 
ticipate  in  humoral  response,  The  hypothetical model  is 
shown in Fig. 4. The data reported in our manuscript are 
suggestive of differential requirements for IFN-',/in the in- 
duction of humoral immune response to self (AChR)  and 
foreign (KLH) antigens; however, the study of other self- 
antigens  would  substantiate  this  notion.  The  findings  of 
humoral immune responses observed in KLH-irmnunized 
IFN-gko  (-/-)  mice  are  further supported by previous 
findings in which IFN-gko (-/-)  mice produce antibod- 
ies to a wide variety of pathogens; influenza (17),  Leishma- 
nia major (28), and Herpes simplex virus (29). 
In support of our hypothesis,  it has  long been known 
that cognate T  cell-B cell interactions involve several re- 
ciprocal receptor-counterreceptor interactions. One of such 
interactions  is  CD28-CTLA-4/B7  signaling.  A  role  for 
CD28/B7 signaling in humoral immune response has been 
documented; human CTLA-4Ig therapy (30) and anti-B7-2 
mAb treatment (31) of mice profoundly blocked antibody 
responses to a nominal antigen priming. This notion is fur- 
ther supported by the report that transgenic expression of 
soluble murine CTLA4-H ~¢ 1 in mice profoundly blocked 
antibody response  to  a  protein  antigen without  affecting 
the T cell responses (32). It is likely that IFN-~/by virtue of 
its abihty to upregulate the basal levels of B7-2 on B  cells 
(33-35) may influence the CD28/B7 costimulation during 
cognate T  cell-B cell interactions, which in turn affect the 
humoral immune response for a self-antigen (M-AChR). 
The fact that anti-self-humoral responses require addi- 
tional cytokine inducible signals  seems  evolutionarily ap- 
propriate.  In the  case  of the AChR,  even extremely low 
levels of autoantibodies are highly detrimental to the func- 
tioning of the neuromuscular junction.  Our findings sug- 
gest that under nonstimulatory circumstances the process of 
cognate help by low affinity anti-AChR T  cells is not fa- 
vored. 
Our results demonstrate that the lack of IFN-,/converts 
an otherwise EAMG-susceptible mouse strain to a disease- 






Figure 4.  Hypothetical  model: how IFN-'y influences the humoral im- 
mune response to self (AChR) and foreign (AChR) antigens in vivo. 
389  Balasa  et al. bility to EAMG  (Table  1).  The  freedom from EAMG in 
IFN-gko mice  was  somewhat  surprising  for two  reasons: 
first,  EAMG  is  an Ab-mediated  disease  (36-38),  and  sec- 
ond, the proinflammatory Thl  cytokine IFN-~/is strongly 
associated  with  cell-mediated  autoimmune  diseases  (39- 
41).  However,  elsewhere  it was shown that IFN-~ is not 
required  for  the  cell-mediated  autoimmune  diseases,  au- 
toimmune encephalomyehtis and diabetes (42, 43), or con- 
fers resistance  to  them  (44).  Thus,  it  appears  that  IFN-~/ 
plays  a  more  essential  role  in  antibody-mediated  than  in 
cell-mediated autoimmune diseases. 
We have  shown in this  study that  the  endogenous  ab- 
sence  of IFN-3~ in  the  periphery prevented  the  develop- 
ment of EAMG in mice to AChR  challenge.  Work from 
our laboratory has shown earlier that the localized expres- 
sion  of IFN-~/  transgene  in  the  neuromuscular junction 
elicited a humoral autoimmune response to an unidentified 
87-kD antigen and provoked a MG-like syndrome in mice 
of the H-2  d haplotype (4).  These findings, as demonstrated 
by diverse approaches in mice of disparate  haplotypes, im- 
plicate IFN-~/as a pivotal player in the pathogenesis of hu- 
moral autoimmunity in the neuromuscular junction. 
In conclusion, the results of this study reveal a differen- 
tial  requirement  for  IFN-~  (a)  in  humoral  immune  re- 
sponse to self (AChR) versus foreign (KLH) antigens,  and 
(b)  the  cytokine  plays  an  important  immunomodulatory 
role in the pathogenesis  of EAMG.  Therefore,  IFN-'y an- 
tagonists  may  prove  beneficial  in  the  treatment  of Ab- 
mediated autoimmune diseases such as MG. 
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